Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - hydroxyethyl starch 130/0.4, quantity: 60 g/l; sodium chloride, quantity: 6.02 g/l; potassium chloride, quantity: 0.3 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of volulyte is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

Australia - English - Department of Health (Therapeutic Goods Administration)

fresenius kabi australia pty ltd - potassium chloride, quantity: 0.3 g/l; sodium chloride, quantity: 6.02 g/l; hydroxyethyl starch 130/0.4, quantity: 60 g/l; magnesium chloride hexahydrate, quantity: 0.3 g/l; sodium acetate trihydrate, quantity: 4.63 g/l - injection, intravenous infusion - excipient ingredients: water for injections; sodium hydroxide; hydrochloric acid - treatment of hypovolaemia due to acute blood loss when crystalloids alone are not considered sufficient. the use of volulyte is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - hydroxyethyl starch 130/0.4 60 g/l; magnesium chloride hexahydrate 0.3 g/l;  ; potassium chloride 0.3 g/l; sodium acetate trihydrate 4.63 g/l;  ; sodium chloride 6.02 g/l;  ;  ;   - solution for infusion - 6 % - active: hydroxyethyl starch 130/0.4 60 g/l magnesium chloride hexahydrate 0.3 g/l   potassium chloride 0.3 g/l sodium acetate trihydrate 4.63 g/l   sodium chloride 6.02 g/l       excipient: hydrochloric acid sodium hydroxide water for injection - treatment of hypovolaemia due to acute blood loss when chrystlloids alone are not considered sufficient. the use of volulyte is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

New Zealand - English - Medsafe (Medicines Safety Authority)

fresenius kabi new zealand limited - hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons); sodium chloride 0.9%; hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons) - solution for infusion - active: hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons) sodium chloride 0.9% excipient: hydrochloric acid sodium hydroxide water for injection active: hydroxyethyl starch 130/0.4 6% (molar substitution 0.38-0.45, av. mwt. 130,000 daltons) excipient: hydrochloric acid sodium chloride sodium hydroxide water for injection - treatment of hypovolaemia due to acute blood loss when chrystlloids alone are not considered sufficient. the use of voluven is not a substitute for the appropriate use of packed red blood cells or fresh frozen plasma.

United States - English - NLM (National Library of Medicine)

mylan pharmaceuticals inc. - etidronate disodium (unii: m16pxg993g) (etidronic acid - unii:m2f465roxu) - etidronate disodium 200 mg - etidronate disodium tablets, usp are indicated for the treatment of symptomatic paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. etidronate disodium tablets are not approved for the treatment of osteoporosis. etidronate disodium tablets are indicated for the treatment of symptomatic paget’s disease of bone. etidronate disodium therapy usually arrests or significantly impedes the disease process as evidenced by: in addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. in many patients, the disease process will be suppressed for a period of at least one year following cessation of therapy. the upper limit of this period has not been determined. the effects of the etidronate disodium treatment in patients with asymptomatic paget’s disease have not been studied. however, etidronate disodium treatment of such patients may be warranted if extensive invo

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin sodium, quantity: 530.1 mg (equivalent: amoxicillin, qty 500 mg); potassium clavulanate, quantity: 119.2 mg (equivalent: clavulanic acid, qty 100 mg) - injection, powder for - excipient ingredients: - curam is an antibiotic alternative to narrow spectrum and broad-spectrum antibiotics for the treatment of polymicrobial infections; especially in mixed gram negative and gram positive infections, and situations where microbial confirmation has not yet been obtained.,infections caused by amoxicillin susceptible organisms are amenable to curam treatment due to its amoxicillin content.,infections caused by beta-lactamase producing amoxicillin resistant organisms are also amenable to curam due to its clavulanic acid content.,susceptibility to curam will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.,curam is indicated for the short term treatment of serious bacterial infections such as:,? upper respiratory tract infections (including ent): e.g. mastoiditis, tonsillitis, otitis media, epiglotitis and sinusitis when accompanied by severe signs and symptoms,? lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar, broncho-pneumonia and community acquired pneumonia,? genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections,? gastrointestinal infections e.g. intra-abdominal sepsis, peritonitis.,? skin and skin structure infections, in particular cellulitis, animal bites, diabetic foot infections, vascular surgery infection/ischaemic soft tissue infection, severe dental abscess,? other infections e.g. septic abortion, puerperal sepsis, post-surgical infections.,? curam is indicated for prophylaxis against infection in major surgical procedures that may be associated with higher risk of infectious complications eg. gastrointestinal surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin sodium, quantity: 1.06 g (equivalent: amoxicillin, qty 1 g); potassium clavulanate, quantity: 238.3 mg (equivalent: clavulanic acid, qty 200 mg) - injection, powder for - excipient ingredients: - curam is an antibiotic alternative to narrow spectrum and broad-spectrum antibiotics for the treatment of polymicrobial infections; especially in mixed gram negative and gram positive infections, and situations where microbial confirmation has not yet been obtained.,infections caused by amoxicillin susceptible organisms are amenable to curam treatment due to its amoxicillin content.,infections caused by beta-lactamase producing amoxicillin resistant organisms are also amenable to curam due to its clavulanic acid content.,susceptibility to curam will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.,curam is indicated for the short term treatment of serious bacterial infections such as:,? upper respiratory tract infections (including ent): e.g. mastoiditis, tonsillitis, otitis media, epiglotitis and sinusitis when accompanied by severe signs and symptoms,? lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar, broncho-pneumonia and community acquired pneumonia,? genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, , female genital infections,? gastrointestinal infections: e.g. intra-abdominal sepsis, peritonitis.,? skin and skin structure infections, in particular cellulitis, animal bites, diabetic foot infections, vascular surgery infection/ischaemic soft tissue infection, severe dental abscess,? other infections e.g. septic abortion, puerperal sepsis, post-surgical infections.,? curam is indicated for prophylaxis against infection in major surgical procedures that may be associated with higher risk of infectious complications eg. gastrointestinal surgery.

Australia - English - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - amoxicillin sodium, quantity: 2.12 g (equivalent: amoxicillin, qty 2 g); potassium clavulanate, quantity: 238.3 mg (equivalent: clavulanic acid, qty 200 mg) - injection, powder for - excipient ingredients: - curam is an antibiotic alternative to narrow spectrum and broad-spectrum antibiotics for the treatment of polymicrobial infections; especially in mixed gram negative and gram positive infections, and situations where microbial confirmation has not yet been obtained.,infections caused by amoxicillin susceptible organisms are amenable to curam treatment due to its amoxicillin content.,infections caused by beta-lactamase producing amoxicillin resistant organisms are also amenable to curam due to its clavulanic acid content.,susceptibility to curam will vary with geography and time. local susceptibility data should be consulted where available, and microbiological sampling and susceptibility testing performed where necessary. amoxicillin/clavulanic acid should be used in accordance with local official antibiotic-prescribing guidelines and local susceptibility data.,curam is indicated for the short term treatment of serious bacterial infections such as:,? upper respiratory tract infections (including ent): e.g. mastoiditis, tonsillitis, otitis media, epiglotitis and sinusitis when accompanied by severe signs and symptoms,? lower respiratory tract infections: e.g. acute exacerbations of chronic bronchitis, lobar, broncho-pneumonia and community acquired pneumonia,? genito-urinary tract infections: e.g. cystitis, urethritis, pyelonephritis, female genital infections,? gastrointestinal infections e.g. intra-abdominal sepsis, peritonitis.,? skin and skin structure infections, in particular cellulitis, animal bites, diabetic foot infections, vascular surgery infection/ischaemic soft tissue infection, severe dental abscess,? other infections e.g. septic abortion, puerperal sepsis, post-surgical infections.,? curam is indicated for prophylaxis against infection in major surgical procedures that may be associated with higher risk of infectious complications eg. gastrointestinal surgery.

United States - English - NLM (National Library of Medicine)

carilion materials management - etidronate disodium (unii: m16pxg993g) (etidronic acid - unii:m2f465roxu) - etidronate disodium 200 mg - etidronate disodium tablets, usp are indicated for the treatment of symptomatic paget’s disease of bone and in the prevention and treatment of heterotopic ossification following total hip replacement or due to spinal cord injury. etidronate disodium tablets are not approved for the treatment of osteoporosis. etidronate disodium tablets are indicated for the treatment of symptomatic paget’s disease of bone. etidronate disodium therapy usually arrests or significantly impedes the disease process as evidenced by: in addition, reductions in pagetically elevated cardiac output and skin temperature have been observed in some patients. in many patients, the disease process will be suppressed for a period of at least one year following cessation of therapy. the upper limit of this period has not been determined. the effects of the etidronate disodium treatment in patients with asymptomatic paget’s disease have not been studied. however, etidronate disodium treatment of such patients may be warranted if extensive invo

Canada - English - Health Canada

sandoz canada incorporated - pamidronate disodium - solution - 3mg - pamidronate disodium 3mg - bone resorption inhibitors